|
Copanlisib in patients with relapsed or refractory follicular lymphoma. |
|
|
|
Consulting or Advisory Role - Bayer |
|
|
Consulting or Advisory Role - Amgen; Bayer; Celgene; Novartis; Roche; Sandoz |
|
|
Consulting or Advisory Role - Janssen; Roche; Takeda |
|
Research Funding - Bayer; Janssen; Roche |
Travel, Accommodations, Expenses - Merck; Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen; Roche |
|
|
Honoraria - Bayer; Celgene; Gilead Sciences; Janssen; Roche |
Consulting or Advisory Role - Bayer; Celgene; Gilead Sciences; Janssen; Roche |
Speakers' Bureau - Celgene; Janssen |
Research Funding - Bayer; Celgene; Janssen; Novartis |
Travel, Accommodations, Expenses - Celgene; Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Celgene; Janssen |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Gilead Sciences; Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
|
|
Research Funding - Amgen; Bayer |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |